The FDA's announcement comes after a paper last summer suggested a slightly higher risk in patients taking the medications.
The drugs known as angiotensin-receptor blockers are taken by millions of people worldwide for conditions such as high blood pressure, heart problems and diabetic kidney disease.
The FDA says its review is the largest of its kind.
The drugs are sold under brand names including Diovan, Micardis and Avapro.
